

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2852-US-CNTSERIAL NO.  
10/802,133

## INFORMATION DISCLOSURE CITATION

DEC 27 2007

Use several sheets if necessary)

APPLICANT

Dirk M. Anderson

FILING DATE

March 16, 2004

GROUP

1646

## U.S. PATENT DOCUMENTS

EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,179,337	12-18-1979	Davis et al			
	4,710,457	12-01-1987	Dupont et al.			
	4,710,473	12-01-1973	Charles F. Morris			
	4,959,314	09-25-1990	Mark et al			
	5,118,667	06-02-1992	Adams et al			
	5,393,739	02-28-1995	Bentz et al.			
	5,447,851	09-05-1995	Beutler et al.			
	5,457,035	10-10-1995	Baum et al.			
	5,578,569	11-26-1996	Tam			
	5,585,479	12-17-1996	Hoke et al			
	5,599,708	02-04-1997	Mundy et al			
	5,658,756	08-19-1997	Rodan et al.			
	5,843,901	12-01-1998	Roeske			
	5,985,832	11-16-1999	Roodman et al			
	6,087,555	07-11-2000	Dunstan et al			
	6,284,485	09-04-2001	Boyle et al			
	6,284,728	09-04-2001	Boyle et al			
	6,284,740	09-04-2001	Boyle et al			
	6,288,032	09-11-2001	Boyle et al			
	6,369,027	04-09-2002	Boyle et al			
	2002/0127637 A1	09-12-2002	Ni et al			
	2002/0150989 A1	10-01-2002	Greene et al			
	6,562,948	05-13-2003	Anderson			
	6,569,430	05-27-2003	Waldmann et al			
	2003/0100069 A1	05-27-2003	Ni et al			
	2003/0100488 A1	05-29-2003	Boyle			
	2003/0103978 A1	06-05-2003	Deshpande et al			
	2003/0104485 A1	06-05-2003	Boyle			
	2003/0144480 A1	07-31-2003	Gorman et al			
	2003/0166097 A1	09-04-2003	Greene et al			
	6,649,164	11-18-2003	Maraskovsky			
	2004/0023313 A1	02-05-2004	Boyle et al			
	2004/0033535 A1	02-19-2004	Boyle et al			
	6,838,262	01-04-2005	Anderson			
	2005/0089522 A1	04-28-2005	Anderson			
	7,063,841	06-20-2006	Gorman et al.			
	7,097,834	08-29-2006	Boyle			
	7,262,274	08-28-2007	Anderson et al.			

EXAMINER

/Elly Gerald Stoica/

DATE CONSIDERED

03/11/2008

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S./

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2852-US-CNT

SERIAL NO.

10/802,133

## INFORMATION DISCLOSURE CITATION

APPLICANT

Dirk M. Anderson

FILING DATE

March 16, 2004

GROUP

1646

(Supplemental sheet)

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	NO
WO 86/00922 A1	02-13-1986	PCT				
WO 90/14363 A1	11-29-1990	PCT				
EP 0514130 A2	11-19-1992	EP				
EP 0526905 A2	02-10-1993	EP				
WO 93/12227 A1	06-24-1993	PCT				
WO 93/21946 A1	11-11-1993	PCT				
WO 95/11308 A1	04-27-1995	PCT				
EP 0727211 A1	08-21-1996	EP				
WO 96/28546 A1	09-19-1996	PCT				
WO 97/00317 A1	01-03-1997	PCT				
WO 97/00318 A1	01-03-1997	PCT				
WO 98/07840 A1	02-26-1998	PCT (for English version, see corresponding EP 0874045, below)				X
AU 71205/98	11-11-1998	AU				
WO 98/28426 A2	07-02-1998	PCT				
WO 98/28426 A2	07-02-1998	PCT				
AU 56180/98	07-07-1998	AU				
EP 0874045 A1	10-28-1998	EP (corresponds. to WO 98/07840, above)				
WO 98/49305 A1	11-05-1998	PCT				
AU 68518/98	11-11-1998	AU				
WO 99/19468 A1	04-22-1999	PCT				
NZ 330400	05-28-1999	NZ				
WO 99/53942 A1	10-28-1999	PCT				
WO 99/58674 A2	11-18-1999	PCT				
WO 01/03719 A2	01-18-2001	PCT				
WO 01/17543 A2	03-15-2001	PCT				
WO 01/18203 A1	03-15-2001	PCT				
WO 03/002713 A2	09-01-2003	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Adams et al., "Complementary DNA sequencing: expresses sequence tags and human genome project," <i>Science</i> , 252: 1651-1656 (1991).
Benjamini et al., <i>Immunology: A Short Course</i> , 2nd edition, Wiley-Liss, New York, p.40 (1988).
Chambers et al., "Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2K <sup>b</sup> AS8 transgenic mouse," <i>Proc. Natl. Acad. Sci. USA</i> , 90:5578-5582 (1993).
Chenu et al., "Transforming growth factor $\beta$ inhibits formation of osteoclast-like cells in long-term human marrow cultures," <i>Proc. Natl. Acad. Sci. USA</i> , 85: 5683-5687 (1988).
Database GenBank, Accession No. AB008426, May 2, 1998.
Database GenBank, Accession No. AF019047, November 22, 1997.

EXAMINER

/Elly Gerald Stoica/

DATE CONSIDERED

03/11/2008

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S./

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2852-US-CNT

SERIAL NO.

10/802,133

## INFORMATION DISCLOSURE CITATION

APPLICANT

Dirk M. Anderson

FILING DATE

March 16, 2004

GROUP

1646

(Supplemental sheet)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Database GenBank, Accession No. AF013170, November 5, 1998.

Database GenBank, Accession No. AF013171, September 19, 1997.

Database GenBank, Accession No. AF019048, November 15, 1997.

Fawthrop et al. "The effect of transforming growth factor  $\beta$  on the plasminogen activator activity of normal osteoblast-like cells and a human osteosarcoma Cell Line MG-63", *J. Bone Miner. Res.*, 7(12):1363-1371 (1992).Fenton et al. "Long-term culture of disaggregated rat osteoclasts: inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PTHrP[107-139]", *J. Cell. Physiol.*, 155:1-7 (1993).Fuller, K., et al., "TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts." *J. Exp. Med.*, 188:997-1001 (1998).Gao, Y. H., et al., "Potential role of cbfal, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis; regulation of mRNA expression of osteoclast differentiation factor (ODF)." *Biochem. Biophys. Res. Commun.* 252:697-702 (1998).Goodwin et al., "Molecular cloning and expression of the Type 1 and Type 2 murine receptors for tumor necrosis factor", *Mol. Cell. Biol.*, 11(6):3020-3026 (1991).Gowen et al., "Preferential inhibition of cytokine-stimulated bone resorption by recombinant interferon gamma", *J. Bone Miner. Res.*, 1(5):469-474 (1986).Hattersley et al., "Human macrophage colony-stimulating factor inhibits bone resorption by osteoclasts disaggregated from rat bone", *J. Cell. Physiol.*, 137:199-203 (1988).

International Search Report, International Application No. PCTJP98/10728, published as WO 98/46644 (1998).

Kaji et al., "Insulin-like growth factor-I mediates osteoclast-like cell formation stimulated by parathyroid hormone", *J. Cell. Physiol.*, 172:55-62 (1997).Kasano et al., "Inhibitory effect of interleukin-4 on osteoclast-like cell formation in mouse bone marrow culture", *Bone Miner.*, 21(3):179-188 (1993).Kukita et al., "Osteoinductive factor inhibits formation of human osteoclast-like cells", *Proc. Natl. Acad. Sci. USA*, 87:3023-3026 (1990).Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor in species specific", *Proc. Natl. Acad. Sci. USA*, 88:2830-2834 (1991).Reddi, A. H. "Bone morphogenesis and modeling: soluble signals sculpt osteosomes in the solid state", *Cell*, 89:159-161 (1997).

Reiger et al., Glossary of Genetics and Cytogenetics, 4th Ed., Springer-Verlag Berlin Heidelberg, New York, p. 17 (1976).

Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death", *Cell*, 76:959-962 (1994).Takada et al., "A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells", *Bone Miner.*, 17:347-359 (1992).Tsuda et al., "Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis", *Biochem. Biophys. Res. Commun.*, 234(1):137-142 (1997).Watanabe et al., "Interleukin-4 as a potent inhibitor of bone resorption" *Biochem. Biophys. Res. Commun.*, 172(3):1035-1041 (1990).Yoneda et al., "Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer", *Cancer Res.*, 55:1989-1993 (1995).

EXAMINER

/Elly Gerald Stoica/

DATE CONSIDERED

03/11/2008

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.G.S./